NASDAQ: GDTCCytomed Therapeutics Ltd Stock
$2.07-0.05 (-2.36%)
Updated Apr 17, 2024
GDTC Price
$2.07
Fair Value Price
N/A
Market Cap
$23.87M
52 Week Low
$1.92
52 Week High
$9.25
P/E
-5.7x
P/B
2.45x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$3.16M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.06
Operating Cash Flow
-$2M
Beta
0.6
Next Earnings
May 29, 2024
Ex-Dividend
N/A
Next Dividend
N/A
GDTC Overview
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company's lead product candidate is CTM-N2D, which consists of expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells, and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. The company was incorporated in 2018 and is headquartered in Singapore.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how GDTC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
GDTC is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
GDTC is good value based on its book value relative to its share price (2.45x), compared to the US Biotechnology industry average (5.83x)
P/B vs Industry Valuation
GDTC is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more GDTC due diligence checks available for Premium users.
Be the first to know about important GDTC news, forecast changes, insider trades & much more!
GDTC News
Valuation
GDTC fair value
Fair Value of GDTC stock based on Discounted Cash Flow (DCF)
Price
$2.07
Fair Value
-$0.25
Undervalued by
936.67%
GDTC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
GDTC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-5.7x
Industry
15.83x
Market
41.64x
GDTC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.45x
Industry
5.83x
GDTC is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
GDTC's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
GDTC's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$10.2M
Liabilities
$548.6k
Debt to equity
0.06
GDTC's short-term assets ($8.50M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GDTC's short-term assets ($8.50M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GDTC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
GDTC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
GDTC vs Biotech Stocks
Cytomed Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.